MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke

NCT01883011 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 571

Last updated 2013-08-30

No results posted yet for this study

Summary

The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their medication within 7 h post-stroke onset.

Conditions

  • Acute Ischaemic Middle Cerebral Artery Stroke

Interventions

DRUG

Piracetam

OTHER

Placebo

Sponsors & Collaborators

  • UCB S.A. - Pharma Sector

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Primary Completion
2001-07-31
Completion
2001-07-31

Countries

  • Argentina
  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Norway
  • Poland
  • Singapore
  • Spain
  • Sweden
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01883011 on ClinicalTrials.gov